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Abstract
A key question yet to be resolved concerns the structure and function relationship of the TCR
complex. How does antigen recognition by the TCR-ab chains result in the activation of distinct
signal transduction pathways by the CD3-gde/z complex? To investigate which part of the TCR-b
chain is involved in TCR signaling, we exchanged different domains of the constant regions of the
TCR-b chain with the corresponding TCR-g chain domains. We show here that hybridoma cells
expressing a chimeric TCR-b chain (bIII) containing intracellular and transmembrane TCR-g amino
acids, together with a wild-type TCR-a (awt) chain, were 10 times more sensitive to antigenic
stimulation compared to cells expressing TCR-awt/bwt chains. This super-signaling phenotype
of the bIII chain was observed in two different TCRs. One speci®c for an alloantigen (I-Abm12) and
one for an autoantigen (I-Ab/MOG35±55). We found that this chimeric awt/bIII TCR had normal
association with CD3-gde and z chains. To investigate the effect of the chimeric bIII chain in
transgenic T cells, we made MOG35±55-speci®c TCR transgenic mice expressing either the awt/bwt
or chimeric awt/bIII TCR. Similar to what was observed in hybridoma cells, transgenic awt/bIII T
cells showed a super-signaling phenotype upon antigenic stimulation. Further studies may help us
understand the effect of increased TCR signaling on autoimmunity and may lead to the
identi®cation of signaling molecules that can be targeted to stop the progression of autoimmune
disorders such as multiple sclerosis.
Introduction
Although the structure and function relationship of the T cell
receptor (TCR) has been investigated for more than two
decades, it remains unknown which of the extracellular,
transmembrane or intracellular domains of the constant region
are responsible for interactions with the different components
of the TCR complex. More importantly, it is also not known
which of these domains are responsible for TCR-induced
proliferation, apoptosis and cytokine production.
T cells express a TCR consisting of clonotypic ab- or
gd-heterodimers associated with the CD3-gde and z chain
homodimers. The ab and gd TCRs show sequence homology
but may still have different structural properties. For example,
a CD3-e epitope detected with the mAb WT31 in the ab TCR
complex is masked in T cells expressing the gd TCR (1,2). In
addition, unlike the ab TCR, the gd TCR is predominantly
expressed without CD3-d (3), and CD3-d de®cient mice lack
ab- but not gd-expressing T cells (4). These examples indicate
that the gd TCR can be expressed at the cell surface in the
absence of the CD3-d chain, and that the structural require-
ment for cell surface expression may differ between ab- and
gd-expressing T-cell subsets.
While the variable region of the TCR-ab and -gd chains is
responsible for antigen recognition, intracellular immuno-
receptor tyrosine-based activation motifs (ITAMs) in the
CD3-gde and z chains are essential for TCR signaling.
However, it is still not certain which domains in the constant
regions of the TCR-ab chains are involved in signal trans-
mission, or how the TCR links antigen recognition to ITAM
phosphorylation and downstream signaling. Interestingly,
structural differences between ab and gd T cells impact on
receptor signaling and ab/gd lineage determination (5). Some
evidence suggests that gd T cells may induce different
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downstream signaling events to ab T cells. For example, gd-
expressing T cells do not depend on CD4 or CD8 for
activation, and have different requirements for PLC-g1 and
protein tyrosine kinase activation of the guanine nucleotide-
exchange factor Vav (6±9).
To better understand the signaling capabilities of the TCR, it
is important to study domains in the TCR-ab that are not
directly involved in antigen recognition, but may in¯uence the
association with the CD3-gde and z chains. To do this, we took
advantage of the similarities and differences between the ab
and gd TCR constant regions by making chimeric a and b
chains containing different lengths of TCR-d and g chain amino
acids, respectively. By studying some of these chimeric TCR
chains, we have previously identi®ed a motif in the connecting
peptide domain of the TCR-a chain (aCPM), and shown that it
is involved in antigen-signaling and association with the CD3-d
chain (10,11). Interestingly, disruption of aCPM affects posi-
tive but not negative selection of thymocytes (10,11), indicat-
ing that the different domains of the TCR carry out specialized
functions. Furthermore, TCR-b connecting peptide domain is
also involved in signaling, since hybridoma cells possessing
mutations within this domain are unresponsive to superantigen
stimulation. In spite of the pronounced signaling defect found,
the interactions of the chimeric TCR-b chain with the CD3-gde
and z chains are preserved (11,12).
The T- and B-cell receptors contain a conserved antigen
receptor transmembrane (CART) motif, suggesting an import-
ant role for this domain in antigen receptor assembly and
function (13). To study the role of the TCR-b chain transmem-
brane domain on TCR structure and function, we utilized a
previously generated chimeric TCR-b chain (bIII) which
contains TCR-g amino acids downstream of the conserved
transmembrane Y145 residue (11). We demonstrate that T
hybridoma and transgenic T cells expressing the chimeric
TCR-bIII chain show super-signaling properties upon stimula-
tion through the TCR with antigen, but not upon CD3 cross-
linking. As the association with the CD3-gde and z chains is
intact, the super-signaling TCR-bIII complex appears to have
normal structure but altered function.
Methods
Cell lines
All cell lines were grown in IMDM supplemented with 5% FCS,
2 mM glutamine, 100 U/ml penicillin G, 100 mg/ml streptomycin
sulphate and 5 3 10±5 M 2-mercaptoethanol (all from Gibco
BRL, Auckland, New Zealand), referred to as complete
medium unless otherwise stated. The human B cell line LG-2
(14) expressing MHC class II DR1 molecule was utilized to
present the superantigen staphylococcal enterotoxin B (SEB)
to T hybridoma cells. The 58a±b± and 58hCD4a±b± have been
previously described (11). The 58a±b± and 58hCD4 are T
hybridoma cell lines which do not express TCR-ab, and in
addition 58hCD4 has been transfected with the human CD4
protein. The Phoenix Eco packaging cell line (a gift from Garry
Nolan, Stanford University School of Medicine, CA) was
cultured in complete medium containing 10% FCS. The
indicator cell line HT-2 (15) was grown in complete medium
with the addition of 20 U/ml IL-2.
Generation of DNA constructs and myelin oligodendrocyte
glycoprotein (MOG) peptide 35±55-speci®c transgenic mice
The Va2.1 and Vb8.1 TCR cDNAs were isolated from the T-cell
hybridoma 3BBM74 as previously described (11). They confer
reactivity to the I-Abm12 alloantigen and the SEB superantigen.
Cloning of the MOG35±55-speci®c T-cell receptor 2D2 (Va3.2
and Vb11) has previously been described (16). For construc-
tion of wild-type and chimeric TCR tg mice, the VJ segments of
the 2D2 a and VDJ of the b chain were ampli®ed by PCR using
2D2 cDNA as template and the following primers: Va-5¢:
GATCGAATTCGTCGACATGCTCCTGGCGCTCC, Va-3¢: GT-
TCTGGGTTCTGGATGTTGGGCTTGATAGATAACTTG, Vb-5¢:
GATCGAATTCGTCGACATGGCCCCCAGGCTCCTT, Vb-3¢:
GTCACATTTCTCAGATCCTCTACAACTGTGAGTCTGG. The
constant a and b chains were ampli®ed by PCR from LXSN-
Va2.1, LXSP-Vb8.1 and LXSP-Vb8.1-bIII (11) as templates for
the constant a, constant b and constant bIII (chimeric b/g)
chains respectively. The following primers were used: Ca-
5¢: CAAGTTATCTATCAAGCCCAACATCCAGAACCCAGAAC,
Cb-5¢: CCAGACTCACAGTTGTAGAGGATCTGAGAAATGT-
GAC, LXSN/P-3¢: GGGCGGGACTATGGTT. The variable and
constant chain PCR products were sewn together in a PCR
using either the Va or Vb upstream primer with LXSN/P-3¢ and
the resulting PCR products were TA cloned in pCR2.1
(Invitrogen, Carlsbad, CA) in accordance with the manufac-
turer's recommendations. The cloned PCR products were
sequenced, excised from the cloning vector with SalI/BamHI,
and cloned into the SalI/BamHI sites of the pHSE3¢ vector (17).
For construction of transgenic mice, the DNA fragment coding
for the TCR chains were excised from pHSE3¢ with XhoI, gel
puri®ed, and microinjected into C57BL/6J oocytes as previ-
ously described (16).
Retroviral infection of 58hCD4 cells
The generation of virus-containing supernatants by transfec-
tion of Phoenix cells and retroviral infection of hybridoma cells
was done as previously described (11). Brie¯y, 2.5 3 105
Phoenix cells/well were seeded in 6-well plates and trans-
fected with 2 mg of retroviral vector the day after using 6 ml of
Fugene6 (Roche Diagnostics, Auckland, NZ) according to the
manufacturer's recommendations. The supernatant, 2 ml,
containing the retroviral particles was supplemented with
10 mg/ml of polybrene (Sigma, Global Science, Auckland, New
Zealand) and added to 2.5 3 105 hybridoma cells. For
selection of positive cells, LXSP-infected cells were added
3 mg/ml of Puromycin (Sigma), and LXSN infected cells
1 mg/ml G418 (Merck, Palmerston North, New Zealand). The
selective drug was added to the cell culture 24 h after
infection. Bulk-infected cells were sorted by ¯ow cytometry for
equal expression of the TCRs and human CD4 chains and
then used in indicated experiments.
Electroporation of 58a±b± T hybridoma cells
For expression of 2D2 TCR and murine CD4 in 58a±b± T
hybridoma cells, pcDNA3/neo (for G418 selection) and
pcDNA/L3T4 (murine CD4) were linearized with PvuI and
ScaI respectively, while pHSE3¢/2D2awt, pHSE3¢/2D2bwt and
pHSE3¢/2D2bIII were linearized with XhoI. The linearized DNA
was precipitated and dissolved in PBS. For electroporation,
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5 3 106 58a±b± T hybridoma cells were electroporated in 200 ml
PBS containing 2 mg pcDNA3/neo, 4 mg pcDNA3/L3T4, 10 mg
pHSE3¢/2D2awt and 10 mg of either pHSE3¢/2D2bWT or
pHSE3¢/2D2bIII at 960 mF and 0.25 kV using a Bio-Rad Gene
Pulser (Bio-Rad, San Diego, CA). Surviving cells were cultured
for 24 h in complete medium after which they were seeded at
5 3 103 cells/well in 96-well plates in complete medium
containing 1 mg/ml of G418. Surviving clones were screened
for Va3.2, Vb11 and mCD4 expression using ¯ow cytometry.
One 2D2 wt and one 2D2 bIII expressing clone was found to
respond to MOG35±55 and therefore selected for this study.
These clones were stained with anti CD4/PE and anti TCR-b/
FITC and sorted for equal expression of TCR and mCD4, using
a FACSVantage Flow Cytometry System (Becton Dickinson).
Antibodies, peptides and superantigen
The MOG35±55 peptide was synthesized by Mimotopes
(Clayton, Australia) and was more than 90% pure, con®rmed
by HPLC. The peptide sequence for mouse MOG35±55 is
MEVGWYRSPFSRVVHLYRNGK. SEB was purchased from
Toxin Technology, Inc. (Sarasota, FL). The antibodies B20.1
(anti Va2.1), RR3-16 (anti Va3.2), H28±710 (anti TCR-a
constant region), F23.1 (anti Vb8), RR3-15 (anti Vb11), H57±
597 (anti TCR-b constant region), 145±2c11 (anti CD3-e),
H129.19 (anti mouse CD4), RPA-T4 (anti human CD4), or
H146±968A (anti z) were used. All mAbs were either pur-
chased from BD PharMingen (San Diego, CA) or puri®ed from
culture supernatants. Goat anti-rabbit-HRP (Southern
Biotechnology Associates, AL) and goat anti-Armenian
hamster-HRP (Jackson ImmunoResearch Laboratories, Inc.)
were used as secondary antibodies for their respective
primary antibodies.
Hybridoma stimulation assay
For hybridoma stimulation assays, 5 3 104/well hybridoma
cells were seeded in 96-well plates. Hybridoma cells were
stimulation with indicated concentration of the MOG35±55
peptide and 5 3 105/well irradiated (2000 Rad) C57BL/6J
splenocytes. For stimulation with SEB, 2 3 104/well LG-2 cells
and SEB at indicated concentrations were added. The
cultures were incubated for 24 h, after which culture super-
natants were harvested. To quantify the concentration of IL-2
in the culture supernatants, 5 3 103 HT-2 cells in 100 ml were
cultured with 100 ml culture supernatant for 24 h and 0.5 mCi/ml
of [3H]thymidine added for the ®nal 6 h of incubation. The
amount of IL-2 was expressed as the HT-2 stimulation index
(SI) (proliferation of HT-2 cells with culture supernatant from
stimulated cells/proliferation of HT-2 cells with culture super-
natant from unstimulated cells). Alternatively, recombinant
IL-2 was added as a standard to calculate total units of IL-2.
T-cell stimulation and proliferation assay
Splenocytes, 4 3 106 cells/well in 24-well plates, from wild-
type and bIII 2D2 mice were stimulated with 10 mg/ml
MOG35±55, and IL-2 (50 U/ml) added on day 2, 5 and 8. On
day 9, cultures were washed twice and 3 3 104 T cells/96-well
mixed with 5 3 105 irradiated splenocytes and antigen. The
T-cell cultures were incubated for 72 h and 0.5 mCi/ml of
[3H]thymidine added for the ®nal 9 h of incubation.
Results
Exchanging transmembrane and intracellular domains of
TCR-b for TCR-g generates a super-signaling TCR
To identify domains in the constant region of the TCR-b chain
important for TCR signal transduction, we have previously
made a number of chimeric TCR-b chains by replacing
domains of the b-chain constant region with homologous
domains of the TCR-g chain. We have previously found that
T cells expressing chimeric TCR-b chains containing TCR-g-
derived amino acids in the TCR-b connecting peptide domain
are defective in response to superantigen. Point mutations
revealed that a single amino acid residue, Q136, located within
the connecting peptide domain of the TCR-b chain controls the
ability of the ab TCR to transmit a full signal (12). In addition,
we have shown that the short intracellular domain of the TCR-a
chain, but not the b-chain, is important for TCR downregulation
but not antigen signaling (18). In this paper, we study the
chimeric TCR-b/g chain, bIII, containing TCR-b-derived
sequences up to and including the conserved transmembrane
tyrosine at position 145, followed by the TCR-g sequence
encoding the remaining transmembrane and intracellular
domains (Fig. 1) (11). The chimeric bIII chain was ®rst
introduced in the 3BBM74 TCR, which confers reactivity to
the I-Abm12 alloantigen and SEB (19). Cells were sorted to
achieve comparable TCR expression level of hybridoma cells
possessing wild-type or chimeric bIII chains. Sorted wild-type
and chimeric bIII chain expressing cells stained with TCR-a,
TCR-b or CD3-e speci®c mAbs showed similar levels of cell
surface expression (data not shown). Upon stimulation with
SEB, T-cell hybridoma cells expressing TCR-awt with chimeric
TCR-bIII responded to almost 10-fold lower concentrations of
SEB compared to hybridoma cells expressing TCR-awt/bwt
(Fig. 2A). Interestingly, upon cross-linking the TCR with plate-
bound anti-CD3 mAb, cells expressing the bwt or chimeric bIII
chains responded similarly (Fig. 2B). Thus, hybridoma cells
with the chimeric TCR-bIII chain are hyper-responsive to
antigenic but not cross-linking signals, indicating that these
stimuli activate distinct signaling pathways.
To further investigate whether this chimeric TCR also shows
super-signaling properties to an autoantigen, we introduced
the chimeric bIII chain into the TCR-b chain of the 2D2 TCR
(Va3.2/Vb11), which speci®cally recognizes the CNS-derived
MOG35±55 peptide (16). We then electroporated 58a±b±
T hybridoma cells with CD4, 2D2 awt/bwt or 2D2 awt/bIII
TCRs and selected for drug-resistant clones. We sorted the
hybridoma cells for equal numbers of surface-expressed 2D2
awt/bwt or 2D2 awt/bIII TCR and CD4 (Fig. 3A, and data not
shown). When these cells were tested for responsiveness to
MOG35±55, hybridoma cells expressing the chimeric bIII TCR
responded better to antigenic challenge, and thus showed a
super-signaling phenotype compared to hybridoma cells
expressing 2D2 awt/bwt TCR (Fig. 3B).
Similar structure of awt/bwt and awt/bIII TCRs
We have previously shown that the awt/bIII TCR associates
normally with the CD3-gde and z chains at the cell surface,
using biotinylation and immunoprecipitation techniques (11).
Furthermore, we immunoprecipitated the 2D2 awt/bwt or awt/
bIII TCR with an antibody speci®c for TCR-b and subsequently
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probed western blots with antibodies speci®c for the TCR-a,
CD3-g, -d, -e, or z chains and found no differences in the
assembly of TCR-ab chains with the TCR complex (data not
shown).
Super-signaling MOG35±55-speci®c TCR transgenic T cells
In order to evaluate the super-signaling chimeric bIII TCR in a
more physiological system, we generated TCR transgenic
mice expressing either the bwt or chimeric bIII chain together
with the wild-type 2D2 Va3.2 chain. We stimulated spleno-
cytes from 2D2 TCR transgenic mice with MOG35±55 and then
expanded the T cells with IL-2 for 9 days. Naive splenocytes
from both 2D2 awt/bwt and awt/bIII mice, and cells cultured
for 9 days with IL-2, expressed similar levels of the Va3.2,
Vb11, CD3e and CD4 molecules at the cell surface (Fig. 4A,
and data not shown). These short-term T-cell lines were then
tested for proliferative responses to antigen and superantigen
stimulation. We found that the T cells expressing the awt/bIII
TCR proliferated better in response to MOG35±55 (Fig. 4B) and
SEB (Fig. 4C), compared to T cells carrying the awt/bwt TCR.
These results indicate that the chimeric bIII chain renders T
cells hyper-responsive to antigenic signals delivered through
the TCR-ab chains, and that the phenotype is not due to
increased TCR expression.
Discussion
The fact that antigen stimulation through the same TCR-ab
chains can be translated into a number of different effector
functions makes the TCR complex a fascinating cell surface
receptor to study. To determine whether the different domains
Fig. 3. Response of awt/bwt or awt/bIII chimeric MOG35±55-speci®c
TCR to MOG35±55. The 58a±b± hybridoma cell line was
electroporated with mouse CD4, 2D2-awt/bwt or awt/bIII TCRs.
Antigen-speci®c clones, one of each, were selected and sorted by
¯ow cytometry. TCR expression levels of 2D2 awt/bwt (thick line) or
awt/bIII (broken line) cells, or no antibody (solid area) were
determined using an antibody speci®c for TCR-Vb11 (A). Clones
were stimulated with irradiated splenocytes and MOG35±55.
Supernatants from quadruplicate cultures of each antigen
concentration were assayed for IL-2 concentration using the HT-2
bioassay (B). The y-axis represents the stimulation index of HT-2
cells (CPM with antigen/CPM with no antigen). One representative
experiment out of three is shown.
Fig. 4. Proliferative response of 2D2 transgenic T cells to MOG35±55
and SEB. Splenocytes from 2D2 awt/bwt or awt/bIII TCR transgenic
mice were stimulated with MOG35±55 and expanded with IL-2 for
9 days. TCR-Vb11 expression of 2D2 awt/bwt (thick line) or awt/bIII
(broken line) cells, or no antibody (solid area) after 9 days is
displayed (A). Similar results were found using anti-TCR-Va3.2 or
CD3-e mAbs (data not shown). Proliferation of 2D2 awt/bwt or awt/
bIII T cells in response to MOG35±55 (B) and SEB (C) is depicted.
One representative experiment out of three is shown.
Fig. 1. Amino acid sequence of TCR-b, TCR-g or chimeric TCR-b/g
(bIII) chains. The C-terminal sequences of the TCR-b, TCR-bIII and
TCR-g chains are shown using the single-letter amino acid code.
Only the sequence of the connecting peptide, transmembrane, and
intracellular domains are shown. The box indicates the sequence
derived from TCR-g. For more information see (11).
Fig. 2. Response of awt/bwt or awt/bIII I-Abm12-speci®c TCR to SEB
and anti CD3. The 58hCD4 hybridoma cell line was infected with
I-Abm12-speci®c awt/bwt or awt/bIII TCRs, sorted for similar TCR and
CD4 expression, and then stimulated either with LG-2 cells and SEB
(A), or plate-bound anti CD3e mAb (B). Supernatants from
quadruplicate cultures of each antigen concentration were assayed
for IL-2 concentration using the HT-2 bioassay. One representative
experiment out of four is shown.
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of the TCR chain constant regions may be involved in different
effector functions, we have replaced part of the extracellular
connecting peptide, transmembrane and intracellular
domains of the TCR-ab with the corresponding domains of
the TCR-gd chains. In this way, we have previously found that
the connecting peptide domains of the TCR-a and -b chains
control antigen responsiveness (11,12).
Here, we further analyze the role of the chimeric TCR-bIII
chain, which contains TCR-g amino acids downstream of the
conserved transmembrane Y145 residue. Introducing the
chimeric bIII TCR together with the wild-type TCR-a chain
renders hybridoma cells and transgenic T cells ~10-fold more
sensitive to antigen stimulation (MOG35±55 and SEB), but not to
stimulation by anti-CD3 cross-linking. We have previously
shown that the awt/bIII TCR associates with the CD3-gde and
z chains at the cell surface, using biotinylation and immuno-
precipitation techniques [(11) and data not shown]. Thus, the
super-signaling phenotype of the chimeric bIII TCR is not due
to a change in the assembly of the TCR with CD3-gde or
z chains or higher surface expression of the chimeric TCR
(Figs 3A and 4A). The phenotype of the chimeric bIII chain is
most likely mediated by changes in the transmembrane
domain of the TCR-b chain, since we have previously dem-
onstrated that the short intracellular domain of the TCR-b chain
is dispensable for TCR signaling (18).
The transmembrane domain of the TCR-b chain has previ-
ously been implicated to be involved in TCR signaling. By
introducing point mutations, it has been revealed that TCR-b
transmembrane residues contribute towards both T-cell acti-
vation and apoptosis (20,21). Mutating one or both of the two
conserved tyrosines (Y145 and/or Y155) to phenylalanine in the
transmembrane region of the b chain causes a marked
reduction in antigen responsiveness in mouse hybridoma
cells. Likewise, mutating the conserved transmembrane
C-terminal tyrosine (Y155) to leucine in Jurkat cells affects the
association of the z chain with the TCR complex. Interestingly,
these Jurkat cells show normal IL-2 secretion, but reduced
apoptosis and FasL upregulation in response to anti-CD3
stimulation (22±24). However, the super-signaling phenotype
of the chimeric TCR-bIII might be due to a different mechan-
ism, since both the TCR-b and TCR-g chains possess the
transmembrane Y145 and Y155 residues (11). In addition, a
chimeric TCR-b chain, bII, containing TCR-g-derived amino
acids from the conserved transmembrane residue K151 and
downstream paired with the wild-type TCR-a chain does not
show any super-signaling properties [(11) and data not
shown]. The only difference between these two chimeric
TCR-b chains is between positions 146±150 in the transmem-
brane domain, where bII encodes the TCR-b-derived amino
acids EILLG, and bIII the TCR-g derived amino acids LLLLL.
Thus, the super-signaling phenotype is most likely attributed to
the replacement of the conserved E146 and G150 amino acids
in the TCR-b chain to L146 and L150.
Transmembrane domains often possess an a-helix structure
with every three/four amino acids ending up in the same
vertical plane (13). The spacing between E146 and G150 is four
amino acids and they are therefore likely to face the same
side. BaÈckstroÈm et al. (11) have previously reported that,
whereas single point mutations within the aCPM do not affect
TCR signaling, substituting three amino acid residues within
the same motif renders the resulting TCR non-functional. This
indicates that small changes are tolerated without affecting the
function of the TCR. It is possible that the E146 and G150
residues of the TCR-b chain are part of an important TCR-b
chain transmembrane motif and interact directly with the CD3/
z complex and that the interface is made up by a number of
additional amino acids, all of which contribute to the inter-
action. Substituting E146 and G150 with the corresponding
TCR-g leucine residues in the bIII chimera could therefore be
structurally tolerated, but with altered TCR signaling. On the
other hand, the corresponding TCR-g leucine residues, in
conjunction with residues found further downstream, might be
part of an important motif in the gd TCR complex which makes
the bIII chain interact more ef®ciently in comparison to bII (or
the wild-type TCR-b chain) and thus renders this TCR hyper-
active. Another possibility is that the TCR-g chain leucine
residues are less ef®cient, in comparison to the wild-type
TCR-b chain, in interacting with a transmembrane-resident
molecule involved in TCR-induced inhibition, and therefore
cells expressing the bIII TCR show a ®ctional hyper-
proliferative response.
In summary, the bIII chain generates a TCR with an apparent
super-signaling phenotype which is not limited to one TCR,
since both alloantigen (I-Abm12) and autoantigen-speci®c
(MOG35±55) TCRs expressing this chimeric bIII chain are
hyper-responsive upon antigen stimulation (Figs 2 and 3). We
are currently in the process of investigating how the chimeric
bIII chain affects downstream signaling pathways. In addition,
the super-signaling MOG35±55-speci®c C57BL/6J TCR trans-
genic mice may represent a novel model for studying how
changes in TCR signaling affect the development of an
autoimmune disorder, using the experimental autoimmune
encephalomyelitis model for human multiple sclerosis.
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